Disease Modification of Asthma by molecules derived from TB bacteria

点击翻译按钮获取中文摘要

Tuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they haveevolved over millennia to remain hidden in the body by producing proteins that modulate thehost's immune system. These proteins have been shown to interact with and reduce the body'snatural inflammatory processes.Peptinnovate’s innovationPeptinnovate’s approach is to unlock the anti-inflammatory activity of these proteins and todevelop new medicines for debilitating diseases such as asthma and COPD. Building onevolution, nature's ingenuity and employing Peptinnovate’s drug discovery and developmentskills we have modified these proteins to more drug-like molecules and are progressing thecandidate molecule, PIN201104, to the clinic.AimsFollowing exciting preclinical data in the murine house dust mite (HDM) asthma model forthe lead candidate PIN201104 Peptinnovate will progress the molecule into in vivo and invitro mechanism of action studies to; unravel the mechanism of action of the peptide inasthma animal models and translate this mechanism into an in vitro setting in human cells.These studies will then lead to an in vitro biomarker assay for use in clinical studies in healthyvolunteers and guide phenotypic positioning of PIN201104 in severe, steroid refractiveasthma.Objectives• To perform in vivo studies in murine asthma models to determine if PIN201104effects airway hyperreactivity (asthma)• To perform in vivo studies to ascertain the appropriate dosing regimen and route ofdelivery for PIN201104 for the treatment of asthmaBenefits, outcomes and impactsThe worldwide market for inflammatory disease treatment is substantial (>$70 billion),however recent safety scares have been attributed to a number of key drugs. Peptinnovate’sparadigm shift in potential treatment options will have a profound impact on the lives ofmillions of patients, reducing the burden on the healthcare providers and helping to build asustainable UK biotech company